Milestone map
Milestone map
3 milestones
Scope question and build technical source list
2–3 weeks
Select a specifically scoped biotechnology application — not 'CRISPR' broadly, but a concrete application such as 'base editing for sickle cell disease' or 'CAR-T cell therapy for B-cell lymphoma' — and gather primary sources covering the technical mechanism, current development status, and known challenges. Analysis of publicly available literature, patent databases, and regulatory filings requires no physical lab access.
Proof required
Submit your precisely stated research question and an annotated bibliography of 12–15 sources (peer-reviewed papers, patent filings, regulatory documents, or clinical trial registrations) with each annotation stating the source's contribution to understanding the mechanism, status, or challenge being analysed.
What gets checked
- Question is specific enough to make a 'this application has solved X but not Y' analysis possible — not broad enough to require a textbook-length treatment
- Source list covers at minimum three source types: peer-reviewed research, regulatory or clinical trial registration, and one independent secondary analysis
- Each annotation states the source's specific relevance to the analysis question — not just a content summary
Common mistakes
- Scoping too broadly — 'CRISPR applications' cannot be analysed in 4000 words; 'base editing for a specific condition' can
- Relying only on review articles — primary research papers and patent filings reveal technical realities that review articles often smooth over
Resources
Foundationstart here
Depthgo deeper
Masteryfor the dedicated
What a verifier looks for
- Ask the submitter to explain the core technical mechanism of their chosen application in non-specialist terms — confirms genuine understanding beyond source summarisation.
- Ask why this specific application was chosen over a closely related alternative — the answer reveals how precisely they scoped the analysis.
- Ask what the key technical or regulatory barrier to approval or commercialisation is — the literature makes this explicit for almost all biotechnology applications.
Draft technical and regulatory analysis
2–3 weeks
Write the core analysis: the technical mechanism, current development stage, technical challenges, and regulatory pathway. For each technical challenge, identify whether it is a fundamental scientific barrier, an engineering scaling problem, or a regulatory/manufacturing issue — this distinction is what separates genuine analysis from description.
Proof required
Submit a 2000–3000 word draft covering: (1) the technical mechanism in specific molecular or cellular terms, (2) current development stage with evidence, (3) the primary technical barriers with specific names, and (4) the regulatory pathway including key agencies and outstanding requirements.
What gets checked
- Technical mechanism is described at the molecular or cellular level — not just 'it edits genes' but what molecular machinery is involved and why that creates the specific challenge being addressed
- Development stage is referenced to a specific source — not 'it is in development'
- Technical barriers are named specifically — not 'off-target effects' but 'guide RNA off-target editing at paralogous genomic loci'
Common mistakes
- Describing what the technology does rather than analysing it — 'The system uses Cas9 to cut DNA' is description; 'The core barrier is on-target delivery efficiency to non-dividing cells' is analysis
- Not distinguishing between scientific barriers and regulatory barriers — these have completely different solutions and timelines
Resources
Foundationstart here
Depthgo deeper
What a verifier looks for
- Ask the submitter to name the primary technical barrier and explain why it has not yet been solved — this probes analytical depth beyond description.
- Ask what a specific clinical trial failure or development setback reveals about the technical challenges — real setbacks are well-documented in public registries.
- Ask how the regulatory pathway differs from a standard small-molecule drug — knowing which framework applies confirms genuine domain understanding.
Complete analysis with ethical dimensions and Q&A
1–2 weeks to complete and schedule review
Extend the analysis to cover societal, ethical, and commercial dimensions. Present to a biotechnologist or biomedical researcher for a Q&A that probes both technical understanding and analytical reasoning.
Proof required
Submit your complete analysis (3500–5000 words) including the technical analysis from M2, plus sections on ethical/societal considerations and commercial viability. Include a written Q&A record showing specific challenges from the reviewer and your responses. The reviewer must be named and their biotechnology background stated.
What gets checked
- Ethical section engages with a specific contested dimension of this application — not generic 'genetic modification raises ethical questions' but the specific issues raised by this particular application
- Q&A record shows at least two technical challenges from the reviewer and substantive responses that demonstrate reasoning beyond the submitted text
- Commercial viability assessment references specific factors — cost of goods, reimbursement pathway, competition — not generic 'large market'
Common mistakes
- An ethical section that lists generic bioethics principles without applying them to the specific characteristics of the application
- A reviewer with only biology teaching experience and no research or industry exposure — the Q&A must challenge technical and analytical claims at domain depth
Resources
Depthgo deeper
What a verifier looks for
- Ask what the strongest argument against developing this application is — probes whether the submitter has genuinely engaged with the opposition case.
- Ask what a competing or alternative approach to the same problem exists and how it compares technically — confirms the analysis is positioned within the landscape.
- Verify the reviewer has biotechnology research or industry experience — a general biology academic may not be able to challenge technical mechanism claims in this subfield.
Part of